Abstract
The evaluation and management of patients with cancer with suspected immune checkpoint inhibitor (ICI) colitis have distinct challenges within the setting of the coronavirus disease 2019 (COVID‐19) pandemic. The approach to the treatment of patients with ICI colitis requires consideration of the risks and benefits of individual immunosuppressive medications and varies based on the presence of a concurrent COVID‐19 infection.
MeSH terms
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents, Immunological / adverse effects
-
Antiviral Agents / therapeutic use
-
COVID-19 / diagnosis
-
COVID-19 / etiology*
-
COVID-19 Drug Treatment*
-
Carcinoma, Non-Small-Cell Lung / therapy
-
Colitis / chemically induced*
-
Colitis / diagnostic imaging
-
Colitis / drug therapy
-
Diarrhea / chemically induced
-
Diarrhea / virology
-
Feces / chemistry
-
Female
-
Glucocorticoids / therapeutic use
-
Humans
-
Immunotherapy / adverse effects*
-
Leukocyte L1 Antigen Complex / analysis
-
Lung Neoplasms / therapy
-
Middle Aged
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
Antiviral Agents
-
Glucocorticoids
-
Leukocyte L1 Antigen Complex
-
pembrolizumab
-
tocilizumab